| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
John P Bilbrey is Director at OLPX and has filed Form 4s across 5 companies. John P Bilbrey's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $13.0M at current prices.
Historically, John P Bilbrey's trades have earned a below-average insider score of 49/100 across 12 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -21.3%.
The biggest single holding is TPR (~$5.8M) as Director. Net of sales, the TPR filings show accumulation of 28,880 shares.
John P Bilbrey has 119 Form 4 filings on record from April 2017 to October 2026, across 5 companies: Director at Colgate-Palmolive (CL), 2017–2026; Director at Olaplex (OLPX), 2023–2025; Director at Elanco Animal Health (ELAN), 2019–2024, and 2 more.
The 143 reported transactions were 66 stock awards, 54 option or other derivative awards, 15 open-market purchases and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 13 purchases worth about $2.1M and 4 sales worth about $1.7M.
The largest open-market purchase was 183,493 shares of OLPX at an average $2.05 on August 19, 2024, about $376K. Twelve months later OLPX was down 32%.
The largest open-market sale was 6,329 shares of CL at an average $91.59 on May 1, 2024, about $580K. Twelve months later CL was down 1%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | OLPX Olaplex Holdings, Inc. | Director | Buy | 76,825 | $1.75 | $134,695.03 | +31.8% | -17.4% | -41.3% | |
| Aug 19, 2024 | OLPX Olaplex Holdings, Inc. | Director | Buy | 183,493 | $2.05 | $376,160.65 | +315.8% | -14.9% | -32.2% | |
| May 1, 2024 | CL Colgate Palmolive Co | Director | Sale+OE | 6,329 | $91.59 | $579,695.89 | -17.3% | +9.3% | -1.3% | |
| Sep 15, 2023 | OLPX Olaplex Holdings, Inc. | Director | Buy | 8,100 | $2.29 | $18,549.00 | +16.2% | +14.6% | +7.1% | |
| Aug 15, 2023 | OLPX Olaplex Holdings, Inc. | Director | Buy | 50,000 | $2.63 | $131,630.00 | New | -38.0% | -35.1% | |
| May 9, 2023 | CL Colgate Palmolive Co | Director | Sale+OE | 5,703 | $80.81 | $460,868.55 | -17.8% | -4.6% | +15.9% | |
| Nov 11, 2022 | ELAN Elanco Animal Health Inc | Director | Buy | 7,500 | $13.24 | $99,267.00 | +21.9% | -2.3% | -20.9% | |
| May 11, 2022 | ELAN Elanco Animal Health Inc | Director | Buy | 10,000 | $22.03 | $220,284.00 | +41.3% | -8.1% | -57.8% | |
| Feb 14, 2022 | CL Colgate Palmolive Co | Director | Sale+OE | 4,917 | $78.66 | $386,772.70 | -18.4% | -0.1% | -5.9% | |
| May 5, 2021 | CL Colgate Palmolive Co | Director | Sale+OE | 3,941 | $80.95 | $319,023.95 | -17.9% | -1.8% | -4.3% |